Overview

At RegMedNet we truly believe that regenerative medicine is going to revolutionize modern healthcare. The field comprises a multidisciplinary mix of experts, from regulators to manufacturers to researchers; RegMedNet is a network that unites all members of this diverse community, enabling the connection and collaboration that will help this exciting field move forward at an even faster rate.

Why should you join?

First and foremost, you should do so because, by joining the network and sharing your news and knowledge, you will be contributing towards the development of this ground-breaking and promising field. But, at a more personal level, this network also gives you the opportunity to connect with your peers and help gain knowledge and connections that may be useful to your work, whether it is research or regulation.

RegMedNet users can be Members, Networkers or Leaders. Those with the most site activity will be Leaders, who have maximum exposure on the Network and use it to really lead debate and progression. As the number of Leaders is limited, inactive Leaders will be reverted to Networkers; Networkers are still able to generate posts, they just don’t appear on the home page. The basic and automatic user type upon sign up is Member, which allows messaging, following and commenting. This user-type setup allows us to ensure that posts by RegMedNet users will be appropriate for the site, without having a block on signup that makes registration fussy and time-consuming for the user.

Features

• Fast access to editor- and user-generated news, discussion and opinion from the field of regenerative medicine
• Ability to follow your peers and colleagues so that you are notified of their updates
• 1-2-1 video chats for private use or publication on the network
• Easy blogging and vlogging
• 1-2-1 private messaging
• Quick sharing to your social media accounts
• Simple-to-use Q&A forum
• Straightforward site navigation and search ability
• Free open access content from relevant Future Science Group publications

Advisory Board

Curtis Asante
Project Manager, UK Regenerative Medicine Platform (Immunomodulation Hub) at King’s College London (UK)

Alain Vertes
Managing Director, NxR Biotechnologies GmbH (Switzerland)

Alexey Bersenev
Director, Advanced Cell Therapy Lab at Yale University, Advanced Cell Therapy Lab at Yale University (US)

Lee Buckler
Vice President, Business and Corporate Development, RepliCel Life Sciences

Timothy Caulfield
Professor, University of Alberta (Canada)

Emily Culme-Seymour
Director at London Regenerative Medicine Network, London Regenerative Medicine Network (UK)

Joseph Dawson
Communications Manager, Genetics Policy Institute

Alan Fernandez
Associate Director, Genetics Policy Institute

Don Gibbons
Senior Science and Education Communication Officer, California Institute for Regenerative Medicine

Victoria English
Editor, MedNous, a publication of Evernow Publishing Ltd

Dusko Ilic
Reader in Stem Cell Science, King’s College London (UK)

Paul Kemp
CEO and CSO, Intercytex Ltd

Paolo Madeddu
Professor, Universitity of Bristol

Chris Mason
Professor, University College London, UK

Kirstin Matthews
Fellow for Science and Technology Policy and Program Manager at Baker Institute

Michael H. May
President & CEO, CCRM

Norio Nakatsuji
Professor, iCeMS/Inst Front Med Sci, Kyoto Univ. and Advisor, Kyoto Stem Cell Innovation, Inc (Japan)

Marjan Rafat
Postdoc in Radiation Oncology, Stanford University (US)

Alan Regenberg
Director of Outreach and Research Support, Johns Hopkins Berman Institute of Bioethics (US)

Susan L. Solomon
CEO and Co-Founder, The New York Stem Cell Foundation Research Institute (US)